Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS' actual-use study shows 90% of subjects act in accordance with Questran OTC label.

This article was originally published in The Tan Sheet

Executive Summary

QUESTRAN OTC "ACTUAL USE" STUDY SHOWS 90% OF SUBJECTS COMPLY WITH LABEL by consulting a physician before using the drug or by opting not to use the drug, Bristol-Myers Squibb reported at a May 13 joint meeting of FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees in Bethesda, Md. The group met to consider whether Questran and Questran Light Rx treatments for hypercholesterolemia are appropriate candidates for OTC marketing.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087054

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel